Product Name: Paclitaxel trevatide
CAS No: 1075214-55-9
Purity: 95%
Molar Mass: 5109.36
Chemical Formula: C257H308N32O79
Synonyms: ANG1005
Storage: Store at -20℃
Sequence: {Paclitaxel-T}FFYGGSRG{Paclitaxel-K}RNNF{Paclitaxel-K}TEEY
Application: Paclitaxel Trevatide (CAS: 1075214-55-9) is a novel therapeutic agent that combines paclitaxel, a widely used chemotherapy drug, with trevatide, a peptide-based compound. This innovative combination aims to enhance the effectiveness of paclitaxel in treating various types of cancer, including breast cancer, ovarian cancer, and lung cancer. Paclitaxel exerts its anti-cancer effects by inhibiting microtubule depolymerization, thereby disrupting cell division and inducing apoptosis (programmed cell death) in cancer cells. Trevatide, on the other hand, is designed to target specific receptors or proteins present on cancer cells, potentially enhancing the delivery of paclitaxel to tumor tissues and improving its efficacy. By combining these two agents, Paclitaxel Trevatide offers a synergistic approach to cancer treatment, with the potential to increase tumor response rates, prolong survival, and reduce adverse effects associated with conventional chemotherapy. Clinical trials are underway to evaluate the safety, efficacy, and therapeutic potential of Paclitaxel Trevatide in cancer patients, with the goal of providing new treatment options for individuals affected by these devastating diseases.
